Abstract: The present invention is directed to a method for analyzing the presence of a bacterial pathogen in a clinical sample comprising the steps of (i) at least partially isolating nucleic acid from said sample, characterized in that said nucleic acid is selected from a group consisting of either total nucleic acid, total DNA or total RNA, (ii) quantifying the amount of nucleic acid comprising a preselected sequence which is specific for said bacterial pathogen, and (iii) determining whether said amount of nucleic acid comprising a preselected sequence which is specific for said bacterial pathogen exceeds a first predetermined cut off value.

Abstract: Thus, the invention provides a new method for generating a multi purpose cost/benefit analysis based on the generation of a multi dimensional database. Starting from this database, different models for various medical scenarios can be created. More precisely, the present invention is related to a method and a database for optimizing design, delivery and implementation of innovative products in healthcare. More precisely, a current treatment scenario of a patient is being loaded from a memory, a default case or a stored scenario from previous customer interviews or publication. The current treatment scenario is modified by input relating to new options such as application of a new health care product. Effects on the current healthcare provider's cost, resource utilization and medical outcome record are determined. Viewpoints of single or various stakeholders involved can be activated. Multiple scenarios can easily be created, so stakeholders can investigate sensitivity of their scenario to key uncertainties.

Abstract: The present invention is directed to a method for analyzing the presence of a bacterial pathogen in a clinical sample comprising the steps of (i) at least partially isolating nucleic acid from said sample, characterized in that said nucleic acid is selected from a group consisting of either total nucleic acid, total DNA or total RNA, (ii) quantifying the amount of nucleic acid comprising a preselected sequence which is specific for said bacterial pathogen, and (iii) determining whether said amount of nucleic acid comprising a preselected sequence which is specific for said bacterial pathogen exceeds a first predetermined cut off value.

Abstract: The present invention is directed to methods and kits for isolation of bacteria from biological samples. In such methods antibodies specific for eukaryotic cells, which are deficient in a bacteria-binding Fc-terminus, are used for separating eukaryotic cells from biological samples.